Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 194.40 | 2.17% |
| CAC 40 | 8,177.89 | 157.58 | 1.96% |
| DAX 40 | 26,437.67 | 573.05 | 2.22% |
| Dow JONES (US) | 53,356.12 | 1,569.40 | 3.03% |
| FTSE 100 | 10,829.21 | 190.78 | 1.79% |
| HKSE | 24,520.10 | 600.60 | 2.51% |
| NASDAQ | 25,736.51 | 364.50 | 1.44% |
| Nikkei 225 | 61,919.30 | 269.33 | -0.43% |
| NZX 50 Index | 14,058.52 | 275.07 | 2.00% |
| S&P 500 | 7,688.62 | 119.70 | 1.58% |
| S&P/ASX 200 | 9,012.30 | 177.80 | 2.01% |
| SSE Composite Index | 3,679.75 | 6.43 | -0.17% |